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Introduction
vitro model relevant to AD (Dataset 4) with robust proof of concept using empirical studies with gene-knockdown, in animal models and in post-mortem human brain.
We first examined expression of genes from the JAK-STAT pathway (KEGG ID hsa04630) in blood from patients with AD compared to unaffected controls, reasoning that post-mortem brain might have more late-stage, secondary changes of inflammation, possibly less relevant to aetiopathological pathways. We used two cohorts, one a multinational longitudinal study (AddNeuroMed -ANM; 105 AD and 114 unaffected age matched subjects; denoted Dataset 1 in this manuscript), and another, a single centre longitudinal study utilising the exact same protocol (Dementia Case Register -DCR; 95 AD and 78 control blood samples (6); denoted Dataset 2). In ANM, 15 of the 47 JAK-STAT genes measured in this dataset were significantly dysregulated when comparing controls with AD subjects (p<0.05 after Bonferroni correction, see ). In DCR, 6 of the 47 JAK-STAT genes were significantly altered (p<0.05), also revealing significance at the pathway level (p-value 0.03). Pvalues obtained in ANM were significantly correlated (p = 4×10 -7 for Spearman correlation, see Fig. 4B ) with those obtained from DCR. We also merged both datasets and repeated the analysis, finding again 15 out of 47 genes were dysregulated (p<0.05) in the AD population when compared with the control population. We then examined JAK-STAT genes in the MCI population compared to unaffected controls in both cohort datasets, finding 10 out of 47 genes dysregulated in both studies, with binomial test being also significant (p-value 9×10 -5 ).
We then examined the expression of JAK-STAT signalling genes in post-mortem brain tissue utilising a study of 129 AD subjects and 101 controls (7) (Dataset 3). In this cohort, 153 JAK-STAT genes were sampled, of which 53 showed significant dysregulation (p-value < 0.05), and binomial exact test reveals that this proportion of significant genes in the JAK-STAT pathway is larger than expected by chance (p-value 2×10 -16 ). With respect to the five genes that were significant in ANM (Dataset 1) and that were also sampled in DCR (Dataset 2), TYK2 (p-value 0.0002), IFNAR2 (0.04) and PIAS1 (2×10 -5 ) were also significantly altered in Dataset 3 (see Table 1 ).
Finally, we also analyzed a previously reported over-expressing mouse model. Knock-down of particular genes on this pathway prevented Aβ induced phenotypes including neurotoxicity and tau-phosphorylation. This experimental dataset contained measurements of 32 JAK-STAT genes, with 8 of these being significantly dysregulated (p-values < 0.05). Binomial testing showed that this proportion of dysregulated genes was higher than expected by chance alone (p-value 0.0001). Of the four genes that were significant in ANM (Dataset 1) and were also sampled in all other datasets (DCR -Dataset 2, Array ExpressDataset 3; and rodent model -Dataset 4), Akt1 (p-value 0.001), Ifnar2 (0.007) and Pias1 (0.016) were also dysregulated in Dataset 4 (see Table 1 ).
Subhead 4: Empirical evidence for JAK-STAT dysregulation in both in vitro and in vivo models of Aβ-induced neurotoxicity
We then further validated these bioinformatics results using empirical studies, measuring the key drivers of the pathway, Jak1, Jak2, Jak3 and Tyk2, in an in vitro model of neuronal toxicity.
Previously, we and many others have demonstrated that rodent neurons exposed to amyloid peptides are susceptible of Aβ-induced toxicity and other phenotypes, including tau phosphorylation and synaptic alterations (8-12).
.. We therefore exposed primary neuronal cultures to 3 µM of oligomerised Aβ42 and real time PCR was performed at 30m, 4h and 24h after Aβ exposure (Fig. 5 ). Hprt1 and Actb were used as housekeeping genes for data normalization. Tyk2 showed a time-dependent increase in expression detectable at 4h (p=0.0077) and maintained up to 24h (p= 0.0063). Jak1 and Jak2 mRNA levels were only significantly increased at 24h with p values of p= 0.024 and p= 0.015, respectively. Jak3 expression was modulated by Aβ at any time point (p>0.05).
We proceeded to test the response of the ak-StatJAK-STAT pathway in an acute in vivo rat model of Aβ toxicity (QPS; Austria GmbH). Five male rats were subjected to bilateral intracerebroventricular injection of 50 µM Aβ1-42 or equal volumes of phosphate buffered saline (PBS). 3h post injection, animals were sacrificed and brains harvested for RNA extraction. We measured the mRNA levels for Jak1, Jak2, Jak3 and Tyk2 in entorhinal cortex from Aβ-injected rats or PBS-sham controls by real time PCR. 3h after Aβ injection, the levels of Jak1 (p-value 0.001), Jak2 (0.0071) and Tyk3 (0.0032) were significantly upregulated (p<0.05) in the brains of these rats but not in control animals (Fig. 6 ) providing further validation for the implication of this pathway in Aβ-mediated toxicity.
Discussion
We have presented here a series of integrated analyses predicated on the underlying hypothesis that co-morbidity of disease can, in some cases, indicate shared genetic susceptibility to disease and that this is manifested most robustly at the level of pathways more than at the level of single genes. By combining genome wide pathway association from all diseases together with their comorbidity with Alzheimer's disease (AD), we identify JAK-STAT signaling as a shared factor correlated with the degree of comorbidity. In the first data-driven phase utilizing gene association data we find this disease cluster to include a series of disorders of immunity and inflammation together with Age Related Macular Degeneration (ARMD) and Type 1 Diabetes Mellitus (T1DM). The association with ARMD is particularly interesting as it has previously been found to be a risk factor for AD (16, 17) , because Aβ is a component of the drusen pathology in the retina of people with ARMD (18, 19) and because the gene most associated with ARMD -CFHencodes for a protein replicated as a biomarker of AD, Complement Factor H (20-22). That our approach of using all-GWAS data in a pathway clustering analysis identifies a relationship between AD and ARMD is all the more remarkable in because this association, in our study, is not driven by CFH. The association we find with T1DM is also intriguing as, although T2DM diabetes is one of the most substantiated risk factors for AD (23), our data now suggests that there might be a relationship also with early onset T1DM that is worth further attention.
However, the most extensive association between shared pathways and disease we find is with disorders of immunity and inflammation. The role of inflammation in AD has been apparent for but the approach we have used here, triangulating between GWAS, real-world and empirical data, and including all disease and all genes, nominates a pathway as part of the aetiopathogenic process that is not identified by such AD gene focused studies.
As in any 'Big Data' approach, there are limitations both to the datasets available and to our use of them. First, in using the GWAS catalogue as a primary data-source, we limit ourselves to disease-gene associations where a significant number of genes have been identified. We do this in order to provide sufficient power for analysis, but acknowledge that the limit of 25 susceptibility genes to enable a disease to enter analysis is both arbitrary and dependent on the size and numbers of studies that happen to have been conducted to date. Almost certainly, we miss information as a consequence of data limitation. Secondly, by segregating genes into pathways we attempt to overcome the intrinsic limitation of GWAS studies, in that biology is mechanistically enacted at the level of pathway and not gene, let alone SNP. Given the large number of SNPs and genes in the human genome, two diseases may have no elements measured in GWAS, or even sequencing studies, in common and yet share an overlapping disease pathogenesis. Measuring association not with SNP but with multiple SNPs across a gene ('genewide association') is one attempt to overcome the limitation; here we go one step beyond this with a pathway-wide association approach. However, in attempting to derive such information from the GWAS data, we are severely limited by current understanding of biological pathways, which is rudimentary at best. This limitation is bound to hinder our derivation of knowledge from information in this context. Thirdly, in seeking to identify diseases comorbid with AD, we have crudely utilised a dataset of concurrent diagnoses, taking no account of some of the confounds or other concerns of conventional epidemiology. Indeed we cannot be sure whether the co-morbidity we observe is due to the disease itself or the drugs used to treat the disease.
However, we note that similar claims-level analyses of real-world clinical data have recently proven valuable in studying genetic and environmental factors shared amongst diseases (34)
We accept the limitations of our approach described above. However, in mitigation of these potential limitations, the datasets we examine are huge; namely, all genetic studies with all genes and all diseases in the first phase, and a dataset of over 6 million people in the second.
Furthermore, we would suggest that some confounds are less critical in the analysis we present here. For example, in studies of risk and protection then clearly understanding direction of effect -whether it is the disease or the treatment that affects risk -is fundamental. However, it becomes less important, potentially irrelevant, where we are determining simply whether the same processes are involved, as both disease and treatment will at some level and in some cases affect the same molecular pathways, which are the axis of our analysis. Finally, despite the limitations of deriving knowledge from data using this approach, the fact that the findings replicate in observational molecular studies in man and in experimental studies in rodents offers strong support to the results.
The JAK-STAT signaling pathway, nominated as a potential target for therapy through datadriven genomics and real-world data in this study, is a key regulator of the response to mediators of inflammation, including cytokines, chemokines (35) and microglia activation (36) . Binding of cytokines (interleukin, interferon and growth factors) and other ligands (such as hormones) to their receptors increases tyrosine kinase activity of Janus Kinases (JAKs, including TYK2), which in turn phosphorylate the receptors and recruit STATs which are themselves then phosphorylated. Subsequent dimerization leads to nuclear translocation and transcription factor activity. Given this critical role in the modulation of the inflammatory response, it is not surprising that JAK-STAT signaling has previously been associated with inflammatory disease and targeted for therapeutics, some of which have been approved for clinical use (37) . The pathway has also been identified as of importance in relation to diabetes (38) In summary, a combined, sequential analysis of GWAS data agnostic to disease type, combined with real-world data of co-incidence of AD with other diseases, nominated JAK-STAT signaling amongst other pathways as a possible underlying pathogenetic mechanism shared across multiple diseases. Remarkably, these diseases -inflammatory disorders, ARMD and Diabetes had previously been implicated as risk factors for AD. Adding to the weight of evidence for JAK-STAT signaling in AD, we subsequently found altered gene expression of the pathway in multiple human and rodent datasets and in empirical studies of Aβ exposure in rodents, both in vitro and in vivo. These data are not the first to nominate JAK-STAT signaling for therapeutic intervention (46), as experiments suggest that humanin (HN) and colivelin (CLN) protect against AD-related neurotoxicity thought its activity in JAK-STAT. However the combination of genetic, human and rodent, observational and empirical data, make a strong case to pursue this pathway as a target for therapies for AD, not least because clinically approved compounds already exist.
This further suggests that this novel integration of orthogonal data is a promising approach to find novel targets in complex disorders.
Materials and Methods

Subhead 1: Overlap of susceptibility genes across human disease
In order to identify biological pathways shared across different diseases, we utilised the GWAScatalogue (5) to obtain a list of all known gene associations with disease derived from GWAS studies. We used the Experimental Factor Ontology (EFO) (47) to identify disease studies, filtering by diseases with at least 25 associated genes, and only including the 25 strongest associated genes ranked by p-value where more than 25 genes have been found to show some association. For any two genes 'α' and 'β' sampled in the GWAS-catalogue, we then calculated the number of KEGG pathways that these 2 genes share, obtaining a gene × gene matrix of which we show a section in Fig. 1 . In order to determine whether susceptibility genes of any given disease share more pathways with the susceptibility genes of any other given disease than expected from chance alone, we used a non-parametric Wilcoxon rank-sum test.
Formally, if we denote the gene × gene matrix as 'n(α,β)' (with 'α' and 'β' being any gene sampled in the GWAS-catalogue), 'A' as the set of genes associated with disease 'A', and 'B' as the set of genes associated with disease 'B', the first sample 'S+' of our test becomes:
While the second sample 'S-' becomes:
Then, a one-tailed Wilcoxon rank-sum test compares 'S+' against sample 'S-'. The statistical results of this comparison determine whether diseases 'A' and 'B' share more pathways than expected from chance according to their GWAS associations.
Subhead 2: Contribution of biological pathways to diseases
Given that the results from the analysis described above suggested an intersection between AD and inflammatory diseases and hence confirming known associations, as discussed in the results and discussion sections, we subsequently focussed on this overlap. For each inflammatory disease sampled in the GWAS-catalogue that had statistical power for subsequent analysis (see below), we calculated a so-called pathway load for each KEGG pathway. This is a numeric value that represents the proportion of susceptibility genes that a given disease has on a given KEGG pathway. Given disease 'A' and pathway 'p', the pathway load is equal to the number of susceptibility genes that disease 'A' has on pathway 'p', divided by the total number of times that any associated gene of disease 'A' is annotated as belonging to any KEGG pathway.
Formally, if we denote 'm(A,p)' as the number of genes of disease 'A' that belong to pathway 'p', the pathway load is:
to control for diseases whose genes may have been more thoroughly studied, and therefore included in more KEGG pathways, than less studied diseases.
Subhead 3: Shared contribution of biological pathways to disease comorbidity with AD
We determine the comorbidity of inflammatory diseases with AD using the US National Hospital To test for statistically significant differences in RNA-expression in these 4 datasets for a given pathway, we use a per gene general linear model (GLM) with a binomial link function, which models AD status (two levels per person -either AD patient or control) as a function of RNAexpression while controlling for a number of covariates (gender, age and sampling centre). The p-values we report correspond to the RNA-expression variable per gene.
Subhead 5: Proof of concept in an in vitro rat model of Aβ exposure
In order to explore JAK-STAT signaling in vitro, primary neuronal cultures were generated from Sprague Dawley E18 rat embryos by papain dissociation according to the manufacturer's instructions (Worthington, Lakewood, NJ, USA) and cultured as previously described (52).
Briefly, brains were harvested and maintained in sterile PBS, hippocampi and cortices were dissected out using a dissection microscope, triturated using a sterile glass Pasteur pipette and maintained in serum-free medium. Viable cells were counted using a hemacytometer. Neurons were plated in Neurobasal medium supplemented with B27, 0.30% glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, at a density of 300,000 cells/ml in plates coated with poly-D-lysine and incubated at 37°C in 5% CO2 atmosphere. Neuronal cultures were treated 7-9 days post-plating.
Aβ1-42 peptide was purchased from Dr. David Teplow (California, UCLA) and was resuspended in 100% 1,1,1,3,3,3 hexafluoro-2-propanol (HFIP) at a final concentration of 1 mM.
For complete solubilisation the peptide was homogenized using a Teflon plugged 250 μl Hamilton syringe. HFIP was removed by evaporation in a SpeedVac, Aβ1-42 resuspended at a concentration of 5 mM in dimethylsulfoxide (DMSO) and sonicated for 10 minutes. Oligomers were prepared as previously described (53): Aβ1-42 was diluted in PBS to 400 μM and 1/10 volume 2% sodium dodecyl sulfate (SDS) in H2O added. Aβ was incubated for 24 hours at 37°C
and further diluted to 100 μM in PBS followed by 18 hours incubation at 37°C. Rat primary neuronal cultures were treated with 3 µM Aβ for either 4h or 24h. These time points were selected based on the commonly observed time progression of changes in RNA after Aβ treatment.
Subhead 6: Proof of concept in an in vivo rat model of Aβ exposure
We further tested whether the observations made in vitro were also found in in vivo models. Each one of these 15 genes has been associated through a GWAS study with at least one of these diseases. Although performed for each disease in the GWAS Catalogue using the 20 most strongly associated genes (i.e. lowest p-value), this figure only shows the top 5 genes and only 3 diseases for representational purposes. Susceptibility genes from association studies of multiple diseases overlap in the pathway space.
Although we analyzed 59 diseases with at least 25 susceptibility genes each, for representational purposes the figure shows those classified as either eye disease, immune system disease, or nervous system disease. The color of each square in the table represents the p-value obtained when calculating whether the GWAS-genes of diseases A and B overlap in the pathway space more than would be expected from chance. Full data is presented in supplementary Fig. S1 . Results from datasets 1 (ANM) and 2 (DCR). Axis represent p-values from each dataset. The solid line shows the a linear regression, with confidence intervals in grey shading. Names are shown for the most significant genes that were also sampled in dataset 3. Human study cohorts with the variables used in the linear model (ANM-AddNeuroMed; DCRdementia case register; AE-ArrayExpress -see methods for details)
